Skip to main content
. 2021 Apr 21;15(11):1852–1863. doi: 10.1093/ecco-jcc/jjab065

Figure 2.

Figure 2.

[A] Efficacy responses in the overall treatment interruption subpopulation at baseline and Weeks 24 and 52 of OCTAVE Sustain, and [B] Kaplan–Meier curves of time to treatment failure during OCTAVE Sustain in induction remitters and induction responders but non-remitters. The overall treatment interruption subpopulation comprised 174 patients who had 8 weeks of tofacitinib induction therapy [10 or 15 mg b.d.] and were randomised to placebo in OCTAVE Sustain. Clinical response was defined as a decrease from induction study baseline total Mayo score of ≥3 points and 30%, plus a decrease in rectal bleeding subscore of ≥1 point or an absolute rectal bleeding subscore of 0 or 1. Endoscopic improvement was defined as a Mayo endoscopic subscore of 0 or 1. Remission was defined as a total Mayo score of ≤2 with no individual subscore >1, and a rectal bleeding subscore of 0.  aIncludes seven patients who received tofacitinib 15 mg b.d. in OCTAVE Induction, and two patients without clinical response were randomised into OCTAVE Sustain [protocol deviations]. b.d., twice daily; N, number of patients treated in the treatment group; n, number of patients with efficacy response.